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ABSTRACT 30 
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Objective:  The newest findings on literature utilization relevant to gynecologic 31 
oncology were published by Thomson Reuters during June 2013 as determinants of 32 
journal standing.  Our objective was to assess the different metrics reported for relative 33 
impact and cost for journals relevant to gynecologic oncology. 34 
Methods:  55 journals were evaluated for Impact Factor (IF), 5 Year IF, Immediacy 35 
Index, Cited Half Life, Eigenfactor score (EF), Article Influence (AI) scores and 36 
subscription costs obtained from publisher information.  37 
Results:  CA-A Cancer Journal for Clinicians had the highest IF (101.78) & AI (24.502).  38 
The top EF cancer-specific journals were the Journal of Clinical Oncology, Cancer 39 
Research, Clinical Cancer Research and Oncogene.  Rankings for Gynecologic 40 
Oncology (409 articles, 18,243 citations) were IF= 3.929, 43/55, EF=0.038, 28/55, AI= 41 
1.099, 44/55, all higher than the previous year.  The IF improved from the 5 year IF in 42 
31 journals, including Gynecologic Oncology, 29/31.  Subscription costs for Gynecologic 43 
Oncology compared favorably to other journals. 44 
Conclusions:  The high utilization of review information in CA-A Cancer Journal for 45 
Clinicians and Nature Review Cancer illustrated by the IF coupled with a relatively low 46 
number of articles and short cited half life indicates that they serve as a leading source 47 
of quoted cancer statistics (CA-A Cancer Journal for Clinicians).  Rankings for 48 
Gynecologic Oncology and the International Journal of Gynecologic Cancer have 49 
improved  Regardless of specialty size, the Impact Factor for Gynecologic Oncology is  50 
respectably strong.  The decreased IF in 44% of the journals may reflect the 51 
international economy’s effect on cancer research. 52 
 53 
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Introduction 54 
The great commission of gynecologic oncology is to advance the field.  To this end, new 55 
information enters the literature and reaches individuals in practice and in training.  We 56 
have examined the extent to which this information is cited using information formulated 57 
by Journal Citation Reports on the ISI Web of Knowledge [1].  In particular, this 58 
examination compares gynecologic oncology-specific citations to citations in a variety of 59 
journals that have published reports relevant to gynecologic oncology.  The metrics 60 
considered here move considerations of quality and worthiness to readers beyond 61 
subjective views of reputation and command the attention of authors, sponsors and 62 
advertisers, while suggesting how metric improvement can be achieved. 63 
 64 
Methods 65 
The 55 journals selected for inclusion in this report all had published findings relevant to 66 
gynecologic oncology annually in the period in 2010-2012.  Data on citations were 67 
obtained from Journal Citation Reports (JCR) on the ISI Web of Knowledge published 68 
by Thomson Reuters on subscription to the University of Kentucky libraries.  The 69 
following definitions are used: 70 
Impact Factor 2012 = A/B where  71 
A = the number of times that articles published in that journal in 2010 and 2011 were 72 
cited by articles in indexed journals during 2012 and  73 
B = the total number of "citable items" published by that journal in 2010 and 2011. 74 
("Citable items" are usually articles, reviews, proceedings, or notes; not editorials or 75 
letters to the editor) [2]. 76 
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5 Year Impact Factor:  Average number of times articles from the journal published in 77 
the last five years have been cited in 2012.  This measure can better gauge the impact 78 
of journals in fields where the influence of published research evolves over a longer 79 
period of time [3]. 80 
Immediacy Index 2012 = A/B where 81 
A = the number of times articles published by the journal in 2012 were cited in indexed 82 
journals during 2012 83 
B = the number of articles, reviews, proceedings or notes published by the journal in 84 
2012 [4]. 85 
Cited Half Life: the median age of the articles in the journal that were cited by other 86 
journals during 2012 [4]. 87 
Eigenfactor score:  The Eigenfactor Score is measured using the 2012 citations in 88 
relation to citable items from the five previous years.  While the Impact Factor weighs 89 
each citation to a journal equally, the Eigenfactor Score assigns a greater weight to 90 
those citations coming from influential journals, allowing these journals to exert greater 91 
influence in the determination of the rank of any journal which they reference.  The 92 
Eigenfactor Score does not count journal self-citations.  The sum of Eigenfactor Scores 93 
for all journals is 100; each journal's Eigenfactor Score is a percentage of this total 94 
[5,6,7]. 95 
Article Influence Score: The journal's Eigenfactor Score divided by the fraction of 96 
articles published by the journal.  This determination is normalized so that the sum total 97 
of articles from all journals is 1 [8]. 98 
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Thus, the mean Article Influence Score is 1.00 across the universe of journals.  99 
Consequently, a score greater than 1.00 indicates that articles in that particular journal 100 
have above-average influence, while a score less than 1.00 indicates that articles in that 101 
journal have a below-average influence. 102 
Cost Comparisons: Subscription costs were obtained by visiting the web sites for each 103 
publication.  Cost of some institutional subscriptions were obtained from the University 104 
of Kentucky library. 105 
Results 106 
Metrics of Citation  55 journals were evaluated.  The Proceedings of the National 107 
Academy of Science of the United States published the most articles (3800) in 2012, 108 
followed by the International Journal of Radiation Oncology Biology Physics (908), the 109 
International Journal of Cancer (713), Cancer (650), and Clinical Cancer Research 110 
(642), Table 1. Gynecologic Oncology published more articles in 2012 than 41 of the 111 
journals (380 articles), while the International Journal of Gynecologic Cancer published 112 
more articles than only 29 of the journals (236 articles).  The articles cited in 2012 for 113 
publications in 2010-11 define the Impact Factor and CA-A Cancer Journal for 114 
Clinicians, the New England Journal of Medicine, the Lancet, Nature Review of Cancer 115 
and the Journal of the American Medical Association ranked with the highest Impact 116 
factors.  Gynecologic Oncology ranked 43rd with an Impact Factor of 3.929, while the 117 
International Journal of Gynecologic Cancer ranked 52nd with an Impact Factor of 1.941, 118 
Table 1.  Immediacy defined in terms of same year publication and citation was highest 119 
for CA-A Cancer Journal for Clinicians, the New England Journal of Medicine, the 120 
Lancet, the Journal of the American Medical Association and Lancet Oncology with 121 
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Gynecologic Oncology ranking 42nd and the International Journal of Gynecologic 122 
Cancer ranking 54th.  The staying power of articles as defined by the median age 123 
published in other journals in 2012 (Cited Half Life, in years) was highest for the 124 
American Journal of Obstetrics & Gynecology, Cancer, the Journal of the National 125 
Cancer Institute, Advances in Cancer Research and the Journal of the American 126 
Medical Association with Gynecologic Oncology ranked 18th and the International 127 
Journal of Gynecologic Cancer ranked 33rd, Table 1.   Journal citations over a five year 128 
period weighted for influential journals (2008-2012: Eigenfactor score) were highest for 129 
the Proceedings of the National Academy of Science of the United States, the New 130 
England Journal of Medicine, the Journal of Clinical Oncology, Lancet, and Cancer 131 
Research, while Gynecologic Oncology ranked 28th and the International Journal of 132 
Gynecologic Cancer ranked 40th.  The Article Influence Score can be taken as a 133 
measure of average influence of a journal’s articles five years after publication and by 134 
this measure CA-A Cancer Journal for Clinicians, the New England Journal of Medicine, 135 
Nature Review Cancer, Lancet, Cancer Cell and the Journal of the American Medical 136 
Association scored highest (>10), while Gynecologic Oncology demonstrated above 137 
average influence and the International Journal of Gynecologic Cancer showed 138 
influence well below average.  139 
Our survey of the 2011-2012 period revealed that ~15% of papers cited in Gynecologic 140 
Oncology had been published in Gynecologic Oncology.  In addition, surveying the 141 
Gynecologic Oncology sections of the Journal of Clinical Oncology and of Cancer, 142 
showed that ~17% and ~5% of the references were to papers published in Gynecologic 143 
Oncology. 144 
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Examination of Cost   The most relevant subscription costs to gynecologic oncologists 145 
are likely to be Gynecologic Oncology & the International Journal of Gynecologic 146 
Cancer (Table 2 line A), Cancer and the Journal of Oncology (Table 2 line B) and 147 
Obstetrics & Gynecology and the American Journal of Obstetrics and Gynecology 148 
(Table 2 line C) totaling $2465 for members, $3003 for non-members and $8983 for 149 
libraries (Table 2 line 3).  The total subscription cost to libraries and institutions for all 55 150 
journals considered here is $109,512 and is ~5 times the cost to individual members 151 
(Table 2 line E).  The mean cost to members of the 55 journals considered (Table 2 line 152 
F: $554+129 (SEM)) compares well with the subscription cost of Gynecologic Oncology 153 
($563 journal alone, $625 annual membership with complementary journal 154 
subscription).  However, subscription costs to the 6 journals most relevant to 155 
gynecologic oncology (Table 2 line D) are much less than the mean cost of subscription 156 
to 6 journals in the group of 55 journals under consideration (Table 2 line G). 157 
Discussion 158 
Ranking of the top 10 Impact Factor journals correlated well with the 5 year Impact 159 
Factor, Immediacy Index and Article Influence Score in that the same journals ranked in 160 
the top 10 for each of these categories (Table 3).  Only one of the top 10 Impact Factor 161 
journals was in the top 10 of the Number of Articles published in 2012, while 4 were in 162 
the top 10 of Total Citations in 2012 and 4 were in the top ten rank for Cited Half-life.  163 
Half of the top ten Impact Factor journals were among the journals with a top ten Eigen 164 
Factor score (Table 3).  Thus, annual citation performance is least correlated with the 165 
number of articles published and connected about half the time with citations received, 166 
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their median half life and Eigen Factor score.  Consequently the metrics of citation are 167 
not driven by the volume of articles published. 168 
Gynecologic Oncology was above the median ranking in terms of articles published, 169 
cited half-life and total citations for 2012 (Table 3), but it was below the median ranking 170 
in all other measures.  The International Journal of Gynecologic Cancer was above the 171 
median ranking in articles published, but below the median ranking in all other 172 
measures (Table 3). 173 
Journals that publish reviews (CA-A Cancer Journal for Clinicians, Nature Review of 174 
Cancer, Nature Reviews Clinical Oncology) are often cited with high immediacy and 175 
short half-life because they are subject to annual updating (and do not necessarily occur 176 
as citations in the most influential journals as indicated by the Eigen Factor metric).   177 
Improvement in the current Impact Factor relative to the previous five years was 178 
observed with 31 journals (56%), while the citation rate fell in 44% of the journals 179 
considered.  Thus, a narrow 6% margin separates the journals that demonstrate 180 
improving citation from those that do not.  Two tactics that could serve Gynecologic 181 
Oncology to stay on track with improving annual Impact Factor scores could be to 182 
include more reviews on gynecologic malignancies and to implement the inclusion of 183 
annual statistics on gynecologic malignancies.  Such statistics should include and 184 
expand the gynecologic malignancies reported on beyond those covered in CA-A 185 
Cancer Journal for Clinicians so that statistics uniquely available in Gynecologic 186 
Oncology would push its Impact Factor higher.  Importantly, gynecologic cancer reviews 187 
and gynecologic cancer statistics should be made available on an Open Access basis to 188 
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maximize their utilization and contribution to the Impact Factor of Gynecologic 189 
Oncology. 190 
Considered in the spectrum of medical specialty journals, Gynecologic Oncology is well-191 
positioned.  Of twenty seven selected medical specialties that were examined (Table 4), 192 
gynecologic oncology which ranked 22nd in physician number (n=1007 [9,10]) had it’s 193 
lead journal’s Impact Factor ranked 13th.  The Impact Factor for Gynecologic Oncology 194 
(3.929) was better than the median Impact Factor for journals in small specialties (49-195 
1854 physicians, median = 2.649) and better than the median Impact Factor for the lead 196 
journals of all specialties considered here (median = 3.569).  Mid sized specialties 197 
(4493-19131 physicians) had lead journals with a greater median Impact Factor (5.644).  198 
Large specialties (27651-90269 physicians) had a median Impact Factor (3.877) slightly 199 
lower than Gynecologic Oncology.  Considered in these terms, the current Impact 200 
Factor for Gynecologic Oncology is quite strong and respectable among journals for 201 
medical specialties.  Impact Factors >10 considered here (Table 1) were either for multi-202 
specialty journals or multi-discipline journals.  We believe that Gynecologic Oncology 203 
currently serves both private practice and academic gynecologic oncologists extremely 204 
well because of it’s targeted content.  We also believe that as a group, gynecologic 205 
oncologists are proud and very competitive.  In this regard, we feel that an expectation 206 
exists for journal metrics that continuously improve.  We believe that there is no down-207 
side to improving these metrics for those in private practice as well as in academic 208 
medicine and that the better the journal metrics, the better the Society of Gynecologic 209 
Oncologists will fair in the eyes of advertisers and sponsors.  210 
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In summary, Gynecologic Oncology performs well in terms of citation metrics and cost.  211 
It should be possible to further improve these metrics by introducing reviews and 212 
statistics on gynecologic malignancies. 213 
The role of the medical journal must loom in the perspective of practitioners as a 214 
trustworthy source of information that carries both influence and advice.  In this role it 215 
unifies the past with the present and must be counted on to have an ongoing outreach 216 
to future discovery and innovation.  Authors want to publish in a quality place that draws 217 
attention to their work, a place that will be good enough to contribute to their career 218 
advancement.  Readers want a source of significant information that is worthy of their 219 
time and subscription cost.  The measure of quality and time worthiness has moved 220 
beyond subjective evaluation and now takes on the metrics of utilization, which while 221 
not totally perfect, provide comparative numeric standards that, like it or not, do 222 
command attention, especially of sponsors and advertisers.  Not to be overlooked are 223 
new models embracing digital communication that have an influence on authors, 224 
readers, patients, sponsors and advertisers through information that reaches them 225 
through the Internet, Open Access, social media, blogs, Twitter, search engines, etc.  In 226 
the end, the metrics of citation utilization will both influence and be influenced by an 227 
evolution of awareness brought forward by technology.  As this occurs, journals must 228 
not lose sight of the significance of peer review  [2].  This is the single most important 229 
process that can re-craft the submission by utilizing expert reviewers that raise 230 
questions, the answers to which can be incorporated in the final publication to enhance 231 
it’s quality [11].  In the end, with the literature practically “bursting at the seams” with the 232 
diverse opportunities made possible by the digital revolution [12], it will be quality that 233 
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determines readership and citations.  The future holds but one thing and that is to 234 
continue to evolve so that specialty information is useful to those in the field of 235 
gynecologic oncology [13]. 236 
 237 
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